Adagene Inc. (ADAG) stock
ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.48−0.12 (-7.50%)
Close on Nov 17, 2026Market cap $87.66MP/E –Yield –
Adagene r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $22.03M, down 23.4% from the year before. The highest annual figure on record is $81.34M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.03M | -23.4% |
| FY2024 | Dec 31, 2024 | $28.78M | -21.4% |
| FY2023 | Dec 31, 2023 | $36.64M | -55.0% |
| FY2022 | Dec 31, 2022 | $81.34M | +19.4% |
| FY2021 | Dec 31, 2021 | $68.10M | +103.1% |
| FY2020 | Dec 31, 2020 | $33.54M | +106.9% |
| FY2019 | Dec 31, 2019 | $16.21M | +0.8% |
| FY2018 | Dec 31, 2018 | $16.08M | – |
See a number that looks wrong?